Characteristics of new solid nodules detected in incidence screening rounds of low-dose CT lung cancer screening: the NELSON study

Purpose New nodules after baseline are regularly found in low-dose CT lung cancer screening and have a high lung cancer probability. It is unknown whether morphological and location characteristics can improve new nodule risk stratification by size. Methods Solid non-calcified nodules detected during incidence screening rounds of the randomised controlled Dutch-Belgian lung cancer screening (NELSON) trial and registered as new or previously below detection limit (15 mm3) were included. A multivariate logistic regression analysis with lung cancer as outcome was performed, including previously established volume cut-offs (<30 mm3, 30–<200 mm3 and ≥200 mm3) and nodule characteristics (location, distribution, shape, margin and visibility <15 mm3 in retrospect). Results Overall, 1280 new nodules were included with 73 (6%) being lung cancer. Of nodules ≥30 mm3 at detection and visible <15 mm3 in retrospect, 22% (6/27) were lung cancer. Discrimination based on volume cut-offs (area under the receiver operating characteristic curve (AUC): 0.80, 95% CI 0.75 to 0.84) and continuous volume (AUC: 0.82, 95% CI 0.77 to 0.87) was similar. After adjustment for volume cut-offs, only location in the right upper lobe (OR 2.0, P=0.012), central distribution (OR 2.4, P=0.001) and visibility <15 mm3 in retrospect (OR 4.7, P=0.003) remained significant predictors for lung cancer. The Hosmer-Lemeshow test (P=0.75) and assessment of bootstrap calibration curves indicated adequate model fit. Discrimination based on the continuous model probability (AUC: 0.85, 95% CI 0.81 to 0.89) was superior to volume cut-offs alone, but when stratified into three risk groups (AUC: 0.82, 95% CI 0.78 to 0.86), discrimination was similar. Conclusion Contrary to morphological nodule characteristics, growth-independent characteristics may further improve volume-based new nodule lung cancer prediction, but in a three-category stratification approach, this is limited. Trial registration number ISRCTN63545820; pre-results.

[1]  M. L. R. D. Christenson,et al.  Guidelines for Management of Small Pulmonary Nodules Detected on CT Scans: A Statement From the Fleischner Society , 2006 .

[2]  J. Gurney.  Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part I. Theory. , 1993, Radiology.

[3]  Harry J de Koning,et al.  Limited value of shape, margin and CT density in the discrimination between benign and malignant screen detected solid pulmonary nodules of the NELSON trial. , 2008, European journal of radiology.

[4]  V. Moyer.  Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2014, Annals of Internal Medicine.

[5]  P. V. van Ooijen,et al.  Features of resolving and nonresolving indeterminate pulmonary nodules at follow-up CT: the NELSON study. , 2014, Radiology.

[6]  P. V. van Ooijen,et al.  Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval , 2016, Thorax.

[7]  William Hazelton,et al.  Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force , 2014, Annals of Internal Medicine.

[8]  S. Fedewa,et al.  Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening , 2018, CA: a cancer journal for clinicians.

[9]  R. Munden,et al.  Lung Cancer Risk Associated With New Solid Nodules in the National Lung Screening Trial. , 2017, AJR. American journal of roentgenology.

[10]  A. Bankier,et al.  Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. , 2017, Radiology.

[11]  H. D. de Koning,et al.  Risk stratification based on screening history: the NELSON lung cancer screening study , 2017, Thorax.

[12]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[13]  J. Lortet-Tieulent,et al.  Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening , 2016, CA: a cancer journal for clinicians.

[14]  D. Berry,et al.  Benefits and harms of CT screening for lung cancer: a systematic review. , 2012, JAMA.

[15]  H. Koning,et al.  Lung cancer screening: latest developments and unanswered questions , 2016 .

[16]  Yvonne Vergouwe,et al.  Towards better clinical prediction models: seven steps for development and an ABCD for validation. , 2014, European heart journal.

[17]  Harry J de Koning,et al.  Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. , 2014, The Lancet. Oncology.

[18]  D. Xu,et al.  Nodule management protocol of the NELSON randomised lung cancer screening trial. , 2006, Lung cancer.

[19]  J. Habbema,et al.  Risk‐based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch‐Belgian randomised lung cancer multi‐slice CT screening trial (NELSON) , 2007, International journal of cancer.

[20]  The impact of radiologists’ expertise on screen results decisions in a CT lung cancer screening trial , 2015, European Radiology.

[21]  Matthew B Schabath,et al.  Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial , 2016, PloS one.

[22]  Witold Rzyman,et al.  European position statement on lung cancer screening. , 2017, The Lancet. Oncology.

[23]  J. Gurney,et al.  Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part II. Application. , 1993, Radiology.

[24]  P. V. van Ooijen,et al.  Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. , 2016, The Lancet. Oncology.

[25]  M. Oudkerk,et al.  Small pulmonary nodules in baseline and incidence screening rounds of low-dose CT lung cancer screening. , 2017, Translational lung cancer research.

[26]  H. D. de Koning,et al.  Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. , 2013, American journal of respiratory and critical care medicine.

[27]  M. L. R. D. Christenson,et al.  Smooth or attached solid indeterminate nodules detected at baseline CT screening in the NELSON study: cancer risk during 1 year of follow up , 2010 .

[28]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[29]  Elena B. Elkin,et al.  Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers , 2008, BMC Medical Informatics Decis. Mak..

[30]  O. Miettinen,et al.  CT screening for lung cancer: suspiciousness of nodules according to size on baseline scans. , 2004, Radiology.

[31]  S. Lam,et al.  Probability of cancer in pulmonary nodules detected on first screening CT. , 2013, The New England journal of medicine.

[32]  M. Prokop,et al.  British Thoracic Society guidelines for the investigation and management of pulmonary nodules: accredited by NICE , 2015, Thorax.

[33]  L. Tanoue,et al.  CT Screening for Lung Cancer: Suspiciousness of Nodules According to Size on Baseline Scans , 2006 .